Literature DB >> 20562195

Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features.

Gabriele Valentini1, Giovanna Cuomo, Giuseppina Abignano, Ambrogio Petrillo, Serena Vettori, Alessia Capasso, Domenico Cozzolino, Gianmattia Del Genio, Carlo Santoriello.   

Abstract

OBJECTIVE: To assess internal organ involvement in early SSc at presentation.
METHODS: One hundred and fifteen patients admitted to a tertiary centre because of RP, who did not present any routinely detectable scleroderma-related internal organ involvement, were investigated for ANA and videocapillaroscopy, and underwent history and physical examination to detect symptoms/signs suggestive of SSc. Patients were then subdivided into three groups: (i) early SSc, constituted by patients without clinical manifestations other than RP, but with scleroderma marker autoantibodies and/or typical capillaroscopic abnormalities; (ii) probable SSc, constituted by patients with the same autoantibody and/or capillaroscopic status as early SSc patients, but with any of the following manifestations: digital ulcers/scars, puffy fingers, arthritis, telangiectasia, dysphagia/heartburn, shortness of breath; (iii) UCTD, constituted by patients with a specific (i.e. disease antibody marker) ANA and capillaroscopic findings plus any disease manifestation. All patients were investigated by lung functional study and B-mode echo-Doppler-cardiography. Patients who consented underwent oesophageal manometry.
RESULTS: An inverted mitral E : A ratio (i.e. early scleroderma cardiac involvement) and/or a diffusing lung capacity for CO <80% of the predictive value (i.e. early lung involvement) and/or basal low oesophageal sphincter pressure <15 mmHg (i.e. early oesophageal involvement) were detected in 37/51 probable SSc patients (72%), 8/19 early SSc patients (42%) and 12/45 UCTD patients (27%).
CONCLUSION: A scleroderma-related internal organ involvement was detected in patients from each group and, more importantly, was pre-clinical in a number of cases.

Entities:  

Mesh:

Year:  2010        PMID: 20562195     DOI: 10.1093/rheumatology/keq176

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  19 in total

1.  New ACR EULAR guidelines for systemic sclerosis classification.

Authors:  Sindhu R Johnson
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

Review 2.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

3.  Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels.

Authors:  Serena Vettori; Giovanna Cuomo; Michele Iudici; Virginia D'Abrosca; Veronica Giacco; Giusi Barra; Raffaele De Palma; Gabriele Valentini
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

Review 4.  Early systemic sclerosis-opportunities for treatment.

Authors:  Lazaros I Sakkas; Theodora Simopoulou; Christina Katsiari; Dimitrios Bogdanos; Ian C Chikanza
Journal:  Clin Rheumatol       Date:  2015-02-26       Impact factor: 2.980

5.  Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study.

Authors:  Michele D'Alto; Antonella Riccardi; Paola Argiento; Ilaria Di Stefano; Emanuele Romeo; Agostino Mattera Iacono; Antonello D'Andrea; Serena Fasano; Alessandro Sanduzzi; Marialuisa Bocchino; Ludovico Docimo; Salvatore Tolone; Maria Giovanna Russo; Gabriele Valentini
Journal:  Clin Exp Med       Date:  2017-10-09       Impact factor: 3.984

Review 6.  Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions.

Authors:  Silvia Bellando-Randone; Marco Matucci-Cerinic
Journal:  Curr Rheumatol Rep       Date:  2017-09-18       Impact factor: 4.592

7.  Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.

Authors:  Serena Vettori; Salvatore Tolone; Domenico Capocotta; Rossella Chieffo; Veronica Giacco; Gabriele Valentini; Ludovico Docimo
Journal:  Clin Rheumatol       Date:  2018-02-13       Impact factor: 2.980

Review 8.  The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

Authors:  Lesley Ann Saketkoo; Jeanette H Magnus; Mittie K Doyle
Journal:  Am J Med Sci       Date:  2014-01       Impact factor: 2.378

9.  Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis.

Authors:  Michele Iudici; Serena Vettori; Barbara Russo; Veronica Giacco; Domenico Capocotta; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2016-05-17       Impact factor: 2.980

10.  Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.

Authors:  S Bellando-Randone; G Lepri; C Bruni; J Blagojevic; A Radicati; L Cometi; A De Paulis; M Matucci-Cerinic; S Guiducci
Journal:  Clin Rheumatol       Date:  2015-12-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.